| Literature DB >> 30034377 |
Wei Lu1,2, Yuqing Feng3,4,5, Fanhui Jing1,2, Yang Han1,2, Na Lyu3,5, Fei Liu3,5, Jing Li3,5, Xiaojing Song1,2, Jing Xie1,2, Zhifeng Qiu1,2, Ting Zhu1,2, Bertrand Routy6,7, Jean-Pierre Routy8, Taisheng Li1,2, Baoli Zhu3,4,5,9,10.
Abstract
Composition of the gut microbiota has been linked with human immunedeficiency virus (HIV)-infected patients on antiretroviral therapy (ART). Evidence suggests that ART-treated patients with poor CD4+ T-cell recovery have higher levels of microbial translocation and immune activation. However, the association of the gut microbiota and immune recovery remains unclear. We performed a cross-sectional study on 30 healthy controls (HC) and 61 HIV-infected individuals, including 15 immunological ART responders (IRs), 20 immunological ART non-responders (INRs) and 26 untreated individuals (VU). IR and INR groups were classified by CD4+ T-cell counts of ≥350 cells/mm3 and <350 cells/mm3 after 2 years of ART, respectively. Each subject's gut microbiota composition was analyzed by metagenomics sequencing. Levels of CD4+ T cells, CD8+HLA-DR+ T cells and CD8+CD38+ T cells were measured by flow cytometry. We identified more Prevotella and fewer Bacteroides in HIV-infected individuals than in HC. Patients in INR group were enriched with Faecalibacterium prausnitzii, unclassified Subdoligranulum sp. and Coprococcus comes when compared with those in IR group. F. prausnitzii and unclassified Subdoligranulum sp. were overrepresented in individuals in VU group with CD4+ T-cell counts <350 cells/mm3. Moreover, we found that the relative abundance of unclassified Subdoligranulum sp. and C. comes were positively correlated with CD8+HLA-DR+ T-cell count and CD8+HLA-DR+/CD8+ percentage. Our study has shown that gut microbiota changes were associated with CD4+ T-cell counts and immune activation in HIV-infected subjects. Interventions to reverse gut dysbiosis and inhibit immune activation could be a new strategy for improving immune reconstitution of HIV-1-infected individuals.Entities:
Keywords: CD4 recovery; HIV-infected individuals; butyrate-producing bacteria; gut microbiota; metagenomics sequencing
Year: 2018 PMID: 30034377 PMCID: PMC6043814 DOI: 10.3389/fmicb.2018.01451
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Demographic and clinical characteristics of the study population.
| VU ( | IR ( | INR ( | HC ( | ||
|---|---|---|---|---|---|
| Age (years, IQR) | 33.0 (27.3–39.0) | 31.0 (26.0–34.5) | 37.5 (34.0–44.3) | 29.5 (24.0–45.8) | 0.050 |
| Male gender (No.%) | 26 (100%) | 15 (100%) | 20 (100%) | 30 (100%) | – |
| BMI (kg/m2, IQR) | 20.8 (19.5–24.1) | 23.2 (18.9–24.1) | 22.5 (20.8–24.8) | 23.3 (21.6–25.2) | 0.228 |
| ART duration (years, IQR) | – | 2.7 (2.1–3.0) | 3.7 (3.1–5.2) | – | 0.005 |
| CD4+ T-cell count (cells/mm3, IQR) | 351.0 (182.8–423.8) | 660.0 (539.5–795.0) | 295.5 (214.0–352.0) | – | 0.000 |
| CD4+ T-cell % (IQR) | 22.1 (17.5–25.3) | 31.4 (27.5–38.2) | 21.1 (13.0–25.6) | – | 0.230 |
| CD8+ T-cell count (cells/mm3, IQR) | 648.5 (586.8–1046.0) | 693.0 (623.0–862.5) | 577.0 (479.5–799.0) | – | 0.368 |
| CD8+ T-cell % (IQR) | 51.6 (42.5–56.4) | 33.7 (32.1–40.9) | 43.5 (37.8–50.1) | – | 0.000 |
| CD4/CD8 percentage (IQR) | 0.45 (0.28–0.56) | 0.94 (0.73–1.05) | 0.48 (0.28–0.72) | – | 0.000 |
| Nadir CD4+ T-cell count (cells/mm3, IQR) | 86.0 (44.5–158.3) | 178.0 (107.5–260.0) | 47.5 (34.0–72.5) | – | 0.000 |